Condition

Neoplasms, Lung

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 20 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials20

Recruiting3

Common interventions25

Lead sponsors shown13

Clinical trials

20 shown

A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)NCT07602855 · 2026-09-09

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]NCT07099898 · 2025-08-11

Precision Lung Cancer Survivorship Care InterventionNCT05857995 · 2024-08-16

Study of ESG401 in Adults With Solid TumorsNCT04892342 · 2021-09-14

Remote Monitoring of Lung Cancer Patient-Reported Outcomes Using Moovcare®NCT05011890 · 2021-09-01

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationNCT04699188 · 2021-02-24

ACTIVE_NOT_RECRUITING

NEUWAVE Flexible Probe Study #2NCT03713099 · 2020-07-31

NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the LungNCT03603652 · 2018-06-29

Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung CancerNCT02410603 · 2016-12-01

MARK 1A Series: Percutaneous Microwave Ablation for Patients With Lung Tumor(s)NCT02673021 · 2016-06-08

Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell CarcinomaNCT02549638 · 2015-04-08

A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ SystemNCT02370303 · 2014-08-01

The Immunotherapy of Nasopharyngeal Cancer Using Cancer Stem Cells VaccineNCT02115958 · 2014-03-01

Vaccine Therapy in Treating Lung Cancer Patients With Cancer Stem CellsNCT02084823 · 2014-03-01

A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR MutationsNCT01131429 · 2010-06-01

A Phase I Study of iPS Cell Generation From Patients With COPDNCT01860898 · 2009-09-01

Incidence of Postthoracotomy Pain Following General Anesthesia: A Comparison Between TIVA and Inhalation AnesthesiaNCT00935571 · 2007-10-01

Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based ChemotherapyNCT00290017 · 2006-02-01

Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung AdenocarcinomaNCT00284141 · 2006-01-01

A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.NCT00042679 · 2002-06-01

Common interventions

Leading sponsors

Mayo Clinic 5 Ethicon, Inc. 2 Fuda Cancer Hospital, Guangzhou 2 GlaxoSmithKline 2 Asan Medical Center 1 Chinese PLA General Hospital 1 Eli Lilly and Company 1 Jerod L Stapleton, PhD 1 Novartis Pharmaceuticals 1 Point Therapeutics 1 Sanofi 1 Shanghai Escugen Biotechnology Co., Ltd 1 UNC Lineberger Comprehensive Cancer Center 1

Trial status mix

COMPLETED9

TERMINATED4

RECRUITING3

UNKNOWN2

ACTIVE_NOT_RECRUITING1

WITHDRAWN1

Phase mix

PHASE28

NA6

PHASE15

PHASE32

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.